Literature DB >> 19703163

Catecholamine synthesis and metabolism in the central nervous system of mice lacking alpha-adrenoceptor subtypes.

M A Vieira-Coelho1, M P Serrão, J Afonso, C E Pinto, E Moura.   

Abstract

BACKGROUND AND
PURPOSE: This study investigates the role of alpha(2)-adrenoceptor subtypes, alpha(2A), alpha(2B) and alpha(2C), on catecholamine synthesis and catabolism in the central nervous system of mice. EXPERIMENTAL APPROACH: Activities of the main catecholamine synthetic and catabolic enzymes were determined in whole brains obtained from alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor knockout (KO) and C56Bl\7 wild-type (WT) mice. KEY
RESULTS: Although no significant differences were found in tyrosine hydroxylase activity and expression, brain tissue levels of 3,4-dihydroxyphenylalanine were threefold higher in alpha(2A)- and alpha(2C)-adrenoceptor KO mice. Brain tissue levels of dopamine and noradrenaline were significantly higher in alpha(2A) and alpha(2C)KOs compared with WT [WT: 2.8 +/- 0.5, 1.1 +/- 0.1; alpha(2A)KO: 6.9 +/- 0.7, 1.9 +/- 0.1; alpha(2B)KO: 2.3 +/- 0.2, 1.0 +/- 0.1; alpha(2C)KO: 4.6 +/- 0.8, 1.5 +/- 0.2 nmol.(g tissue)(-1), for dopamine and noradrenaline respectively]. Aromatic L-amino acid decarboxylase activity was significantly higher in alpha(2A) and alpha(2C)KO [WT: 40 +/- 1; alpha(2A): 77 +/- 2; alpha(2B): 40 +/- 1; alpha(2C): 50 +/- 1, maximum velocity (V(max)) in nmol.(mg protein)(-1).h(-1)], but no significant differences were found in dopamine beta-hydroxylase. Of the catabolic enzymes, catechol-O-methyltransferase enzyme activity was significantly higher in all three alpha(2)KO mice [WT: 2.0 +/- 0.0; alpha(2A): 2.4 +/- 0.1; alpha(2B): 2.2 +/- 0.0; alpha(2C): 2.2 +/- 0.0 nmol.(mg protein)(-1).h(-1)], but no significant differences were found in monoamine oxidase activity between all alpha(2)KOs and WT mice. CONCLUSIONS AND IMPLICATIONS: In mouse brain, deletion of alpha(2A)- or alpha(2C)-adrenoceptors increased cerebral aromatic L-amino acid decarboxylase activity and catecholamine tissue levels. Deletion of any alpha(2)-adrenoceptor subtypes resulted in increased activity of catechol-O-methyltransferase. Higher 3,4-dihydroxyphenylalanine tissue levels in alpha(2A) and alpha(2C)KO mice could be explained by increased 3,4-dihydroxyphenylalanine transport.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19703163      PMCID: PMC2765593          DOI: 10.1111/j.1476-5381.2009.00375.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models.

Authors:  M Scheinin; J Sallinen; A Haapalinna
Journal:  Life Sci       Date:  2001-04-06       Impact factor: 5.037

Review 2.  Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters.

Authors:  J A Roth
Journal:  Rev Physiol Biochem Pharmacol       Date:  1992       Impact factor: 5.545

3.  Regulation of tyrosine hydroxylase activity and phosphorylation at Ser(19) and Ser(40) via activation of glutamate NMDA receptors in rat striatum.

Authors:  N Lindgren; Z Q Xu; M Lindskog; M Herrera-Marschitz; M Goiny; J Haycock; M Goldstein; T Hökfelt; G Fisone
Journal:  J Neurochem       Date:  2000-06       Impact factor: 5.372

4.  Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum.

Authors:  N Lindgren; Z Q Xu; M Herrera-Marschitz; J Haycock; T Hökfelt; G Fisone
Journal:  Eur J Neurosci       Date:  2001-02       Impact factor: 3.386

5.  Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice.

Authors:  Marko Huotari; Miklos Santha; Louis R Lucas; Maria Karayiorgou; Joseph A Gogos; Pekka T Männistö
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

6.  Alpha2-adrenoceptors modulating neuronal serotonin release: a study in alpha2-adrenoceptor subtype-deficient mice.

Authors:  J Scheibner; A U Trendelenburg; L Hein; K Starke
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

7.  Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice.

Authors:  M M Bücheler; K Hadamek; L Hein
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

8.  Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum.

Authors:  Leonid Yavich; Jouni Sirviö; Antti Haapalinna; Aarne Ylinen; Pekka T Männistö
Journal:  Eur J Pharmacol       Date:  2003-02-21       Impact factor: 4.432

Review 9.  Sources and significance of plasma levels of catechols and their metabolites in humans.

Authors:  David S Goldstein; Graeme Eisenhofer; Irwin J Kopin
Journal:  J Pharmacol Exp Ther       Date:  2003-03-20       Impact factor: 4.030

10.  Alpha2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A-adrenoceptor subtype.

Authors:  Janne Lähdesmäki; Jukka Sallinen; Ewen MacDonald; Jouni Sirviö; Mika Scheinin
Journal:  Neuropharmacology       Date:  2003-06       Impact factor: 5.250

View more
  1 in total

1.  GPCR dimerization in brainstem nuclei contributes to the development of hypertension.

Authors:  Gwo-Ching Sun; Wen-Yu Ho; Bo-Rung Chen; Pei-Wen Cheng; Wen-Han Cheng; Mei-Chi Hsu; Tung-Chen Yeh; Michael Hsiao; Pei-Jung Lu; Ching-Jiunn Tseng
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.